SR-9009 (Liquid Stenabolic) – 20 mg/mL For Sale

SR-9009 FAQs

Stenabolic / SR-9009

Each batch is bottled and tested in the USA to ensure accuracy and purity. Our Certificates of Analysis confirm that products meet the listed specifications:

• • Date: 09/23/2025
  • Purity Level: 99.68%

SR-9009 Has Demonstrated A Variety Of Effects In Test Subjects, Such As:

• Increased resting metabolic rate
• Cardioprotection
• Regulation of circadian rhythm and sleep patterns
• Enhanced endurance
• Weight loss
• Lowered cholesterol levels
• Lowered bodily inflammation
• Arterial plaque management

 

SR-9009 has shown potential in conditions such as heart failure, COPD (chronic obstructive pulmonary disease), and metabolic syndrome.

More research needs to be completed on human subjects. Studies performed on animals have shown that SR-9009 holds promise as a health-enhancing product.

 

SR-9009 may one day gain widespread acceptance as “exercise in a bottle.” Nevertheless, SR-9009 has yet to be officially approved by the Food and Drug Administration (FDA) for human use. Therefore, it should be considered for laboratory research purposes only at present, not as a complement to aerobic exercise.

 

SR-9009 and Energy Metabolism

Administration of the REV-ERBα agonist SR-9009 has been shown to affect energy homeostasis in animals. Results of a study on goldfish showed that SR-9009 inhibited feeding and decreased body weight and length gain. In addition, the abundance of ghrelin mRNA was lowered in the intestine, while that of leptin-aI increased in the liver.

SR-9009 also decreased plasma glucose levels, accompanied by higher glycolysis and a lower gluconeogenesis rate in the liver, while lipid levels and lipogenic enzyme activities were reduced. Energy expenditure by locomotor activity remained unaffected. All results indicate that REV-ERBα activation via SR-9009 promotes a negative energy balance by reducing energetic inputs and regulating lipid and glucose metabolism.

SR-9009 and Endurance

A 2013 study found that mice treated with SR-9009 could run longer distances and for extended periods than normal mice.

Overexpression of Rev-erb-α in vitro has been shown to increase the number of mitochondria and improve their respiratory capacity. This is a different mechanism from the way that Cardarine increases endurance. Additionally, overexpression or pharmacological activation of Rev-erb-α in vivo resulted in an increased exercise capacity. These studies suggest that Rev-erb-α may one day be utilized as a pharmacological target to enhance muscle oxidative function by regulating gene networks that govern mitochondrial number and function.

SR-9009 and Circadian Rhythm

Synthetic REV-ERB ligands have been shown to alter circadian behavior in mice and the circadian pattern of core clock gene expression in the hypothalamus. This was also observed in a variety of metabolic genes expressed in the liver, skeletal muscle, and adipose tissues, resulting in an increase in energy expenditure.

When administered treatment with a REV-ERB agonist to diet-induced obese mice, obesity decreased as fat mass was reduced, and dyslipidemia and hyperglycemia were markedly improved. These results suggest that synthetic REV-ERB ligands targeting the circadian rhythm may be beneficial for treating both sleep disorders and metabolic diseases. These results suggest that synthetic REV-ERB ligands targeting the circadian rhythm may be beneficial for treating both sleep disorders and metabolic diseases.

SR-9009 and Cardioprotection

Research conducted on REV-ERB-deficient mice revealed significant cardiac myopathy after transverse aortic constriction compared to wild-type control mice, indicating the importance of REV-ERB in protecting the heart from pressure overload. Interestingly, SR-9009 was still able to provide cardioprotective effects even in REV-ERBα/β cardiac-specific double knockout (cDKO) mice.

 

Additionally, when given at peak or trough points of REV-ERB expression, SR-9009 had similar levels of cardioprotection, suggesting that some cardioprotective properties exist outside of REV-ERB. These findings further demonstrate that deletion of REV-ERB accelerates adverse cardiac remodeling in response to pressure overload, illustrating the independent cardioprotective effect of SR-9009.

SR-9009 and the Lungs

In vitro experiments conducted demonstrated that pharmacological activation of REV-ERBα with SR-9009 can reduce the inflammatory response in lung injury by suppressing TLR4-induced NF-κB activation. SR-9009 treatment was effective in providing beneficial effects to metabolism, as it could ameliorate acidosis and hypoxemia by reducing arterial PaCO2 and increasing arterial PaO2, SO2, HCO3-, lactic acid concentration, and blood pH. These results demonstrate that SR-9009 treatment can mitigate sepsis-induced lung injury, suggesting that targeting Rev-Erbα may be a promising strategy for preventing and managing acute lung injury.

 

Cellular research investigates the anti-tumor effects of SR-9009 in the lungs. This data established that SR-9009 is specifically lethal to both chemosensitive and chemoresistant small-cell lung cancer cells. REV-ERBα was found to be involved in the antitumor effect of SR-9009. Additionally, the core autophagy gene Atg5 was identified as a direct downstream target of REV-ERBα, which is suppressed by the REV-ERB agonist. The interaction between REV-ERBα and this autophagy gene prevented autophagy activity, thereby leading to SR-9009 cytotoxicity in SCLC cells.

Data on Our Liquid SR-9009 for Sale

CAS Number: 1379686-30-2

Formula: C20H24ClN3O4S

Molar Mass: 437.940 g/mol

Class: REV-ERB agonist

Storage: Store in a cool, dry place away from direct sunlight to maximize shelf life.

 

• 30 mL of liquid SR-9009 per bottle at a concentration of 20 mg/mL
• Includes a graduated 1 mL glass pipette for convenient measurement.
• Glass bottle with UV resistance to minimize degradation.
• Tamper-proof seal to ensure safety in transit.
• Less than 5% variance in concentration, guaranteeing consistency.
• Formulated and packaged to prevent evaporation in storage.

SKU: 8

Abuse Warning

SR-9009 is an investigational compound still awaiting FDA approval and is not a dietary supplement. At Sports Technology Labs, we are chemical suppliers, not medical doctors, and our expertise is sourcing and quality control. Sports Technology Labs does not encourage or condone consumer use of SARMs products; they are for research purposes only.

 

SARMs should only be used under the supervision and direction of a medical doctor or designated research authority. We strongly discourage the use of SARMs for performance enhancement in sports and bodybuilding, and warn against “bro science” and peer consensus when making decisions about human health.